Novartis AG said a new experimental medicine improved motor function in children with a form of spinal muscular atrophy, the devastating disorder targeted by its gene therapy Zolgensma, in an advanced study.
Novartis Says Drug Helps Children With Spinal Atrophy in Study
Estimated read time
1 min read
You May Also Like
China Boosts Consumer Subsidies, Vows More Funding to Aid Demand
January 8, 2025
Your company’s digital future lies off-screen
January 8, 2025
Africa Gets New Stock Market as Ethiopia Seeks to Woo Investors
January 8, 2025
+ There are no comments
Add yours